bcbs fep glp 1 coverage 2025 Paving the way for expanded GLP-1 | Insights & Events Upcoming Insurance Changes for GLP-1

Protocols are personalized based on your wellness goals and provider recommendations

Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027

Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone

Quality peptide sources provide third-party testing and certificates of analysis

In the donor brain death (BD) rat model, the fusion protein attenuated the inflammatory response induced by brain death and significantly enhanced the insulin secretion function of transplanted islets in response to glucose stimulation both in vitro and in vivo (140)